Bevacizumab (Bev), a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), is primarily used for the treatment of various solid tumors, such as colorectal cancer, non-squamous non-small cell lung cancer, renal cell carcinoma, and breast cancer. This evidence concerns the gene VEGFA and renal cell carcinoma.